BioSupply Trends Quarterly logo
Search
Close this search box.
Subscribe
Summer 2020 - Vaccines
  Download Issue
Share

Up Front

Publisher's Corner
The Critical Need for Vaccines and Higher Vaccine-Compliance Rates
By Patrick M. Schmidt

Features

Image of needle

Exploring New Vaccine Delivery Methods

Illustration of antivaxers

Counteracting the Anti-Vaccine Movement

Provider with patient and mother

Trends in U.S. Vaccine Compliance

Woman holding her shoulder in pain

Myths & Facts: Fibromyalgia

Illustration of ebola virus

An Update on Ebola

image of vaccine vials

In the Shadow of COVID-19, Will Other Vaccine Development Programs Be Left Behind?

BioTrends Watch

Washington Report
Waiver Allows Medicare Patients to Receive Free Telehealth Services
FDA Campaign Designed to Help Consumers Use New Food Label
Finalized Rule Gives Patients More Control Over Their Health Data
Coronavirus Relief Funds to Pay for Care for Uninsured
Reimbursement FAQs
Data Integrity Vigilance: Telling Patient Pandemic Stories
Industry News
Rituxan Superior to Mycophenolate Mofetil in Sustaining Complete Remission in Pemphigus Vulgaris Patients
Competition Among Clinics Increased Influenza Vaccine Rates Among Patients, Study Showed
FDA Approves Biosimilar to Rheumatoid Arthritis Drug
Study of Kevzara from Severe to Critical COVID-19 Patients
Clinical Trial Will Assess IVIG for Treating COVID-19
Novartis Initiates Phase III Trial of Ilaris to Treat COVID-19 Patients with Pneumonia
Central Repository Created for SARS-CoV 2 Clinical Trials
Study Suggests MMR Vaccine May Be Linked with Fewer Deaths from COVID-19

BioFocus

Industry Insight
Are We Finally Closing In On a Universal Influenza Vaccine?
By Keith Berman, MPH, MBA
Patient Profile
Rabies: A Patient's Perspective
By Trudie Mitschang
Physician Profile
Rabies: A Physician's Perspective
By Trudie Mitschang
MyFluVaccine.com

BioSources

BioResearch
Large-Dose Albumin Supplementation Does Not Reduce Mortality or Need for Critical Care Interventions: Retrospective Review
Bleed Protection with up to 14-Day Dosing of Long-Acting Recombinant Factor IX Product in Selected Children with Hemophilia B
BioSupply Trends Quarterly logo
FFF Enterprises logo
Facebook-f Instagram Linkedin-in Youtube
FFF Enterprises.com | Privacy Statement | Terms of Use |

FFF Enterprises.com
Privacy Statement
Terms of Use

©2024 FFF Enterprises, Inc. All Rights Reserved. Property of FFF Enterprises, Inc.

The information provided on this website is not medical advice, nor is it intended to be a substitute for medical advice, diagnosis, and treatment. Always seek the advice of a physician or other qualified health provider with questions concerning a medical condition. Never disregard professional medical advice, or delay seeking it based on information provided on this website.